Agios Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
Agios Pharmaceuticals - Wikipedia Agios Pharmaceuticals Inc is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias [5]
Agios Pharmaceuticals (AGIO) Stock Price, News Analysis Agios markets its therapies directly in the United States and partners with global pharmaceutical companies for commercialization in Europe and other regions Agios went public in 2013 and has maintained its headquarters and core research operations in Cambridge
Agios Pharmaceuticals, Inc. (AGIO) - Yahoo Finance Find the latest Agios Pharmaceuticals, Inc (AGIO) stock quote, history, news and other vital information to help you with your stock trading and investing
AGIO Stock Price Quote | Morningstar See the latest Agios Pharmaceuticals Inc stock price (AGIO:XNAS), related news, valuation, dividends and more to help you make your investing decisions
Agios Pharmaceuticals (AGIO) Heavy EPS Loss Tests Growth‑Led Bullish . . . Agios Pharmaceuticals (AGIO) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue of $19 97 million in Q4 2025 and a basic EPS loss of $1 85, alongside trailing twelve month revenue of $54 03 million and a basic EPS loss of $7 12 Over the past six reported quarters, the company has seen quarterly revenue move between $8 73 million and $19 97
Agios Pharmaceuticals - AGIO - Stock Price Today - Zacks View Agios Pharmaceuticals, Inc AGIO investment stock information Get the latest Agios Pharmaceuticals, Inc AGIO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more